These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34872162)

  • 1. Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
    Reimann P; Ulmer H; Mutschlechner B; Benda M; Severgnini L; Volgger A; Lang T; Atzl M; Huynh M; Gasser K; Grabher C; Mink S; Fraunberger P; Petrausch U; Hartmann B; Winder T
    Br J Haematol; 2022 Feb; 196(3):577-584. PubMed ID: 34872162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
    Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Le Gars M; Sadoff J; Cárdenas V; Heerwegh D; Tesfaye F; Roey GV; Spicer C; Matias SS; Crayne O; Kamphuis T; Struyf F; Schuitemaker H; Douoguih M
    Vaccine; 2024 Jul; 42(19):3938-3952. PubMed ID: 38918103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.
    Roels S; Bruckner M; Sadoff J; Cárdenas V; Tang C; Hagedoorn S; Heerwegh D; Stieh DJ; Le Gars M
    Vaccine; 2024 Sep; 42(22):126159. PubMed ID: 39121698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination.
    Iketani S; Liu L; Nair MS; Chandrashekar A; Mohri H; Wang M; Barouch DH; Huang Y; Ho DD
    Emerg Microbes Infect; 2021 Dec; 10(1):2220-2222. PubMed ID: 34779713
    [No Abstract]   [Full Text] [Related]  

  • 14. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
    Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
    JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review.
    Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Sadoff J; Le Gars M; Brandenburg B; Cárdenas V; Shukarev G; Vaissiere N; Heerwegh D; Truyers C; de Groot AM; Jongeneelen M; Kaszas K; Tolboom J; Scheper G; Hendriks J; Ruiz-Guiñazú J; Struyf F; Van Hoof J; Douoguih M; Schuitemaker H
    Vaccine; 2022 Jul; 40(32):4403-4411. PubMed ID: 35667914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
    Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
    Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination.
    Ivanko I; Ćelap I; Margetić S; Marijančević D; Josipović J; Gaćina P
    Thromb Res; 2023 Aug; 228():137-144. PubMed ID: 37329722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.